-
HEALWELL achieves its 47th total peer-reviewed publication validating its DARWEN™ AI across multiple disease areas and diverse patient populations.
-
HEALWELL presented new scientific validation of DARWEN™ AI at the European Crohn’s and Colitis Organisation (ECCO) meeting, with findings published in the Journal of Crohn’s and Colitis(1).
-
The study conducted with the U.S. affiliate of a large pharmaceutical partner, demonstrated how AI-enriched Canadian patient support program data can generate real-world evidence to support U.S. Medical Affairs and market access initiatives.
-
HEALWELL has secured three additional conference acceptances in 2026 in collaboration with leading global life sciences companies across diabetes, dermatology and inflammatory bowel disease (IBD) research.
TORONTO, ON, March 12, 2026— HEALWELL AI Inc. (“HEALWELL” or the “Company“) (TSX: AIDX) (OTCQX: HWAIF), a healthcare artificial intelligence company focused on preventative care, today announced continued scientific validation of its DARWEN™ AI platform, with new research accepted for presentation at major international scientific conferences, including the European Crohn’s and Colitis Organisation (ECCO) meeting, with publication in the Journal of Crohn’s and Colitis(1). The study, conducted with the U.S. affiliate of a large pharmaceutical partner, demonstrated how AI-enriched Canadian patient support program data can generate real-world evidence to support U.S. Medical Affairs and market access initiatives, creating significant new commercial opportunities with existing pharmaceutical customers.
These new acceptances bring the total number of peer-reviewed publications validating DARWEN™ AI to 47, spanning multiple disease areas and diverse patient populations.
In 2026, HEALWELL has already secured three additional conference acceptances in collaboration with leading global life sciences companies, highlighting the growing adoption of DARWEN™ AI in real-world clinical research and evidence generation. The new clinical research studies examine:
- Treatment patterns of patients with inflammatory bowel disease
- AI-enabled clinical decision support to improve Type 2 diabetes quality standards in primary care
- Suicidal ideation and behaviour in patients with plaque psoriasis receiving systemic therapies
Together, these studies demonstrate how DARWEN™ AI can generate clinical insights from large-scale real-world healthcare data, supporting research, safety analysis and quality improvement initiatives.
Sacha Gera, HEALWELL’s Chief Operating Officer who oversees the Company’s AI division commented, “The scientific team at HEALWELL continues to set the standard for clinically validated AI, producing peer-reviewed research that carries real weight in the global medical community. What is particularly exciting is seeing this work expand globally through collaborations with the U.S. affiliates of our existing pharmaceutical partners, extending the reach and impact of DARWEN™ AI across new markets. Each publication generates new partnership inquiries, which generate new data access, which enables new publications, creating a compounding scientific and commercial moat that becomes harder to replicate with every study.”
Unlocking Real-World Data from the Electronic Health Record
DARWEN™ AI is designed to unlock insights from the vast amount of unstructured clinical data embedded within electronic health records (EHRs), including physician notes, reports and diagnostic documentation. By transforming this previously inaccessible data into structured, research-ready insights, DARWEN™ AI enables healthcare systems, researchers and life sciences companies to better understand disease patterns, treatment outcomes and patient populations in real-world clinical settings.
HEALWELL’s strategy is centered on activating healthcare system data using its clinically validated DARWEN™ AI engine while expanding the distribution of its AI capabilities through partnerships with healthcare providers, health systems, and life sciences companies. Peer-reviewed validation plays a critical role in this strategy, creating true product differentiation in the marketplace. Each new publication strengthens DARWEN™ AI’s scientific credibility, expands its validation across additional disease states and clinical environments, and enables healthcare and life sciences organizations to make informed decisions about which AI partner best meets their needs. This growing body of evidence establishes a defensible foundation for broader adoption across healthcare systems, pharmaceutical research, and population health initiatives.
Across 47 peer-reviewed publications and ethics-approved real-world evidence studies, DARWEN™ AI has demonstrated the ability to analyze millions of clinical records while maintaining research-grade rigor. This growing validation portfolio reinforces the credibility of HEALWELL’s technology within the global academic and life sciences research community.
Expanding Validation Across High-Value Disease Areas
Research validating DARWEN™ AI spans a broad range of therapeutic areas, demonstrating the platform’s versatility across complex healthcare environments, including:
- Cancer and oncology
- Cardiovascular disease
- Chronic disease and internal medicine
- Dermatology
- Gastrointestinal diseases
- Infectious diseases
- Mental health
- Ophthalmology
- Rare diseases
- Social determinants of health
- Substance use and addiction
These studies include diverse real-world patient populations across multiple ethnicities and socioeconomic backgrounds, strengthening DARWEN™ AI’s applicability for population health management, real-world evidence generation and precision medicine initiatives.
By expanding validation across these disease areas, HEALWELL is increasing the clinical utility of its AI platform while creating new opportunities to support healthcare systems, academic researchers and global life sciences companies seeking to generate insights from real-world healthcare data. This growing body of scientific validation also helps build a long-term pipeline of commercial and research opportunities, as healthcare organizations increasingly look to leverage real-world clinical data to improve outcomes and advance medical research.
James Lee, Chief Executive Officer of HEALWELL, commented, “We are building the scientific foundation that will make DARWEN™ the default AI layer for real-world evidence generation in global healthcare. Scientific validation is a critical component of that strategy. Each new peer-reviewed publication strengthens the credibility of DARWEN™ AI and expands its validation across additional disease areas and clinical settings. With 47 peer-reviewed publications and growing, we believe our clinically validated AI will play an increasingly important role in helping healthcare systems and researchers unlock insights from real-world data, improve clinical decision-making and ultimately deliver better patient outcomes.”
Footnotes
Bressler, B. B. et al., “Persistence and treatment patterns of vedolizumab subcutaneous maintenance therapy in patients with inflammatory bowel disease: data from a Canadian cohort,” Journal of Crohn’s and Colitis, Volume 20, Supplement 1, 2026. https://academic.oup.com/ecco-jcc/article/20/Supplement_1/jjaf231.127/8432484
James Lee
Chief Executive Officer
HEALWELL AI Inc.
About HEALWELL AI
HEALWELL is a healthcare artificial intelligence company focused on preventative care. Its mission is to improve healthcare and save lives through early identification and detection of disease. Using its own proprietary technology, the Company is developing and commercializing advanced clinical decision support systems that can help healthcare providers detect rare and chronic diseases, improve efficiency of their practice and ultimately help improve patient health outcomes. HEALWELL is executing a strategy centered around developing and acquiring technology and clinical sciences capabilities that complement the Company’s road map. HEALWELL is publicly traded on the Toronto Stock Exchange under the symbol “AIDX” and on the OTC Exchange under the symbol “HWAIF”. To learn more about HEALWELL, please visit https://healwell.ai/.
For more information:
Pardeep S. Sangha
Investor Relations, HEALWELL AI Inc.
Phone: 604-572-6392
ir@healwell.ai